This study was intended to determine the pharmacological safety of oral ivermectin in pregnant women. A systematic review of information published in the PubMed, MEDLINE, Scopus, Toxline, World Health Organization Clinical Trials Registry, US FDA List, ClinicalTrials, and Cochrane Central Registry databases was conducted from 1990 through 2020. From a total of 73 research articles reviewed, two animal experiments, one clinical and five analytical experiments were studied. Animal studies were found to show that ivermectin was associated with the risk of micarriage, congenital malformations, stillbirth and maternal death. In humans, the effects presented in the animal study could not be determined. It is concluded that clinical studies are necessary to establish the presence of adverse effects in pregnant women from the consumption of ivermectin.

Objectives: To determine if urinary tract infection (UTI) during pregnancy is a risk factor for preeclampsia at the Hospital Belén de Trujillo between 2017-2020. Materials and Methods: An observational, retrospective, analytical case-control study was conducted, which included 102 pregnant women with more than 20 weeks of gestation attended at the Hospital Belén de Trujillo. Two groups were compared: one with preeclampsia and the other without preeclampsia, matched in a 1:2 ratio. The Chi-square test was used to analyze the data, considering significance if the p-value was <5% (p < 0.05). Results: It was found that 79.4% of patients with preeclampsia had a history of UTI during pregnancy, while only 38.2% of the pregnant women in the control group had it. Urinary infection was significantly associated with preeclampsia (OR: 6.2, 95% CI 2.375–16.346, p= 0.000), indicating that p...